Project Grant R01DA065256
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $1.39 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective March 1, 2026, with completion targeted for December 31, 2030. This grant supports research investigating mitochondrial oxidative phosphorylation dysfunction in the comorbid epidemics of HIV-Associated Neurocognitive Disorders (HAND) and Opioid Use Disorder (OUD) in the...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Feinstein Institutes For Medical Research a Project Grant of $1,205,548 (awarded July 15, 2025, with completion by March 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on transposable element expression in the context of HIV-1 and cannabis use. The project, titled "Single Cell Dark Matter in the Context of HIV and Substance Use," develops and applies a...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $9.33 million Project Grant to The Regents of the University of California, San Francisco under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct in vivo imaging and post-mortem research examining the impact of methamphetamine (MA) use on immune dysfunction and HIV reservoir transcription among people with HIV on antiretroviral therapy (ART). The award, effective July 15, 2025 through May 31,...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $731,879 project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 1, 2026 through February 28, 2031. This research initiative will investigate the impact of cannabis use on the NLRP3 inflammasome in people with HIV (PWH), with particular focus on understanding how cannabinoid exposure modulates immune activation...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Alabama at Birmingham a $1.77 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the impact of cannabis use on T cell function in HIV central nervous system (CNS) reservoir seeding, persistence, and neuropathogenesis. The award, obligated on April 15, 2026, with completion targeted for January 31, 2031, supports research examining how...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $456,268 Project Grant on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a two-year research investigation examining antioxidant and cerebral blood flow profiles in people living with HIV (PWH) who use marijuana. The project will utilize advanced edited magnetic resonance spectroscopy (MRS) to assess glutathione...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $198,854 to the University of California, San Diego under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining trajectories of social isolation and loneliness among older adults living with HIV (Human Immunodeficiency Virus) who use methamphetamine. The two-year project, initiated August 1, 2025 and concluding July 31, 2027, will deliver research services including...
- Federal Project Grant Award Summary The National Institute on Drug Abuse awarded UC San Diego a $4.95 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the BRAIN-FOCUSED RESEARCH ON ANTIRETROVIRALS AND METHAMPHETAMINE (BRAIN-FRAME) study. Funded from May 15, 2026, through March 31, 2031, this multidisciplinary research initiative delivers integrated clinical research, neurobehavioral assessment, and biological mechanism investigation to improve...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of North Carolina at Chapel Hill a $804,951 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through May 31, 2030. This award supports research investigating cannabinoid type 1 receptor (CB1R) positive allosteric modulators (PAMs) as potential therapeutic interventions for HIV-1-associated neurocognitive disorders (HAND). The project...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a K24 mentoring grant totaling $192,930 to the University of California, San Diego, effective May 1, 2026, through April 30, 2031, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award provides protected time to develop research mentoring capabilities and train the next generation of patient-oriented researchers investigating the intersection of substance use and Human Immunodeficiency Virus...
The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $1.5 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct translational and cross-species research examining the effects of cannabis use on mitochondrial function in people with HIV (PWH). The award, effective June 1, 2026, through April 30, 2031, supports an integrated research program combining clinical observation with preclinical modeling to investigate whether cannabis use patterns—specifically moderate versus chronic daily use—differentially impact mitochondrial homeostasis in brain macrophages through triggering receptor expressed on myeloid cells (TREM2)-mediated mechanisms. The research addresses a critical gap in understanding central nervous system complications in PWH despite antiretroviral therapy, with particular emphasis on age-related neuropathogenesis in the aging PWH population (average age >55 years). The grant funds a multidisciplinary research approach incorporating three complementary components: a clinical observational cohort study of aged PWH (>50 years) stratified across cannabis use patterns from naive to daily users; personalized ex vivo and in vitro modeling of mitochondrial toxicity in brain macrophages and neurons; and preclinical mouse models including an HIV-induced neurotoxicity model and a TREM2 variant model associated with age-related neuropathogenesis. Research outputs will include biomarker measurements from plasma and cerebrospinal fluid reflecting mitochondrial homeostasis and TREM2 function, advancing understanding of cannabis's potential protective or deleterious effects on HIV-associated neurological complications.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 5/22/26 |